Early Triple Lipid-Lowering Therapy After ACS
Official title: EARLY-BIRD ACS Trial: Early Aggressive Lipid-Lowering Regimen With Bempedoic Acid Initiated for Reducing Dyslipidemia in Patients With Acute Coronary Syndrome
Run by Taipei Medical University Hospital · NCT07824323 · Data updated 2026-11-12
This trial tests whether adding bempedoic acid to high-intensity statin and ezetimibe within 72 hours after PCI helps more adults with acute coronary syndrome reach LDL-C goals than the standard two-drug approach.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Taipei Medical University Hospital Academic / other |
| Locations | 1 site (Taipei, Taipei City) |
| Status | Recruiting |
| Started | August 26, 2026 |
| Main results expected | March 2028 |
| Study ends | December 2028 |
| Registry record updated | September 17, 2026 |
| Trial ID | NCT07824323 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 or older with acute coronary syndrome who had PCI within the last 72 hours and initial LDL-C >= 70 mg/dL.
✕Probably not a fit
Patients with severe hepatic impairment, gallbladder disease history, or intolerance to statins, ezetimibe, or bempedoic acid may not benefit and could be excluded due to safety concerns.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, open-label, blinded-endpoint trial compares triple therapy (bempedoic acid plus high-intensity statin and ezetimibe) to dual therapy (high-intensity statin and ezetimibe) in adults with acute coronary syndrome who recently underwent PCI. Participants with LDL-C >= 70 mg/dL are enrolled within 72 hours of PCI and followed for 12 weeks, with primary outcome assessed as the proportion achieving LDL-C < 55 mg/dL at Week 12. Secondary measures include changes in lipid and inflammatory markers, adherence, and adverse events. The study uses intention-to-treat analysis and is conducted at Taipei Medical University Hospital, with the lead sponsor coordinating the trial.
Why it matters
Potential benefit: If successful, adding bempedoic acid could help more patients reach target LDL-C levels sooner after an ACS, potentially lowering future cardiovascular risk.
How similar studies have gone: Prior lipid-lowering strategies show that combination therapies can improve LDL-C control; this study tests a newer triple-therapy approach in the ACS/PCI setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older. * Confirmed acute coronary syndrome, including ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, or unstable angina. * Percutaneous coronary intervention within the preceding 72 hours. * Baseline LDL-C of at least 70 mg/dL. * Able and willing to provide written informed consent. Exclusion Criteria: * Current use of a PCSK9 inhibitor or fibrate at baseline. * History of symptomatic hyperuricemia or gout. * Severe hepatic impairment, defined as ALT or AST greater than 3 times the upper limit of normal at screening. * Known gallbladder disease, including cholelithiasis or previous cholecystitis. * Known intolerance or contraindication to statins, ezetimibe, or bempedoic acid. * Triglycerides of at least 400 mg/dL at screening. * Estimated glomerular filtration rate below 30 mL/min/1.73 m2 or dialysis. * Active systemic infection or acute inflammatory disease that could interfere with hs-CRP interpretation. * Current participation in another interventional clinical trial. * Pregnancy, breastfeeding, or planned pregnancy during the study period.
Where it's running
-
Taipei Medical University Hospital
Taipei, Taipei City, Taiwan Recruiting
Study contacts
- Principal investigator: Chun-Yao Huang, MD, PhD — Taipei Medical University Hospital
- Study coordinator: Chun-Yao Huang, MD, PhD
- Email: cyhuang@tmu.edu.tw
- Phone: +886-2-2737-2181
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Observational study of achieving LDL targets with Rovazet tablets in dyslipidemia
This study follows patients with dyslipidemia who are prescribed Rovazet to see how well reaching LDL targets works in routine care over 48 weeks.
-
Aspirin 50 mg vs 100 mg with a P2Y12 inhibitor after PCI
This trial tests whether a 50 mg daily aspirin dose, when used with a P2Y12 inhibitor after PCI, works as well as 100 mg with similar safety for people staying on DAPT for 12 months.
-
Smartphone AI help for prehospital ECG readings
This study tests whether using a smartphone AI (GPT-4o) to help prehospital providers read 12-lead ECGs improves accuracy in diagnosing acute coronary syndromes and related conditions.
-
Kodo Millet Porridge and Gut Health in Overweight and Obese Adults
This study tests whether daily intake of Kodo millet porridge for 12 weeks can improve gut bacteria and metabolic health in adults who are overweight or obese.
-
Taiwan green propolis for MASLD and lipid/metabolic issues
This study tests whether Taiwan green propolis capsules can improve blood lipids and body fat in adults with MASLD compared to a placebo over 12 weeks.
-
EHR-guided LDL cholesterol optimization after a heart event
A pharmacist-guided program using electronic health records to help adults in Alberta reach LDL goals after a heart event by adjusting medications and ordering tests.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.